Niedźwiedzi
Pfizer's stock price declines amid market gains; analysts express caution.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Pfizer's stock closed at $23.72 on July 6, 2026, a 2.47% decrease from the previous day, underperforming the S&P 500's 0.72% gain. Analysts have expressed caution due to the absence of near-term catalysts and potential challenges in the company's pipeline.
Kluczowe punkty
- HSBC downgraded Pfizer's rating to 'Hold' from 'Buy,' citing a lack of short-term catalysts and reducing the probability of commercialization for certain pipeline products.
- Pfizer reaffirmed its 2026 financial guidance, maintaining revenue projections between $59.5 billion and $62.5 billion, and adjusted earnings per share between $2.80 and $3.00.
- The stock's price-to-earnings ratio stands at 18.45, indicating a valuation that may be considered reasonable by some investors.
Źródła
- HSBC rebaja la calificación de Pfizer por falta de catalizadores a corto plazoInvesting.com · July 6, 2026
- Pfizer reafffirms 2026 guidance after CFO transition announcementInvesting.com · June 19, 2026
- Pfizer (PFE) Stock Sinks As Market Gains: Here's WhyZacks.com · July 6, 2026
- Pfizer Inc. stock informationYahoo Finance · July 10, 2026
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
